pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cell Therapy · news · pharmadog
← back to Cell Therapy
News · Cell Therapy
309
stories
Aug 24, 26
FDA extends review of Capricor cell therapy; Pain drug startup to go public
biopharma dive
Aug 24, 26
Capricor’s Duchenne therapy has new life after FDA grants 3-month extension
biospace
Aug 24, 26
Cellares, a cell therapy manufacturing specialist, to lay off 100 employees
biopharma dive
Aug 24, 26
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
Aug 21, 26
Capricor investor calls for change as company awaits decision on Duchenne candidate
biospace
Aug 21, 26
Lawmakers urge FDA to enact new China policies after 3 gene therapy trial deaths
biospace
Aug 21, 26
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
Aug 20, 26
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
stat
Aug 19, 26
Amgen cans its TScan partnership; Amylyx reveals $350M offering
endpoints
Aug 19, 26
Dissecting Chinese trial strategy in wake of deaths
stat
Aug 19, 26
Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein
fiercebiotech
Aug 19, 26
STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
stat
Aug 18, 26
Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss
fiercebiotech
Aug 18, 26
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
Aug 17, 26
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
Aug 14, 26
Capricor soars on potential FDA review extension, filing amendments
biospace
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 14, 26
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
Aug 14, 26
Capricor soars on plan to amend DMD filing after adcomm setback
fiercebiotech
Aug 12, 26
Boulevard starts up with $65M to pursue targeted autoimmune drugs
biopharma dive
Aug 11, 26
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
biopharma dive
Aug 11, 26
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
endpoints
Aug 10, 26
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
biospace
Aug 7, 26
Replimune to ride wave of physician support to launch advanced melanoma therapy
biospace
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
Aug 6, 26
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
Aug 5, 26
STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
stat
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
← prev
page 7 of 11
next →